Literature DB >> 4052381

Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids.

J W Lown, A R Morgan, S F Yen, Y H Wang, W D Wilson.   

Abstract

The binding constants for interaction of the anticancer agents mitoxantrone and ametantrone and several congeners with calf thymus DNA and the effects of ionic strength changes have been determined spectrophotometrically. The agents show a preference for certain sequences, particularly those with GC base pairs, and the magnitude of the specificity depends on the specific substituents on the anthraquinone ring system. The binding constant for mitoxantrone with calf thymus DNA in 0.1 M Na+, pH 7, is approximately 6 X 10(6) M-1, and the rate constant for the sodium dodecyl sulfate driven dissociation of mitoxantrone from its calf thymus DNA complex under the same solution conditions and 20 degrees C was determined to be 1.3 s-1. The unwinding angle of mitoxantrone determined independently by viscosity measurements and by a novel assay employing calf thymus topoisomerase shows excellent agreement for a value of 17.5 degrees. The viscosity increase of sonicated calf thymus DNA varies considerably with the substituent on the anthraquinone ring system. Binding studies employing T4 and phi w-14 DNAs in which the major groove is occluded and the reverse experiment with anthramycin-treated calf thymus DNA indicate at least part of the mitoxantrone molecule may lie in the minor groove.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4052381     DOI: 10.1021/bi00336a034

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Potent inhibition of werner and bloom helicases by DNA minor groove binding drugs.

Authors:  R M Brosh; J K Karow; E J White; N D Shaw; I D Hickson; V A Bohr
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

2.  Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts.

Authors:  B S Parker; S M Cutts; C Cullinane; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

3.  A theoretical study of anthracene and phenanthrene derivatives acting as A-T specific intercalators.

Authors:  K X Chen; N Gresh; B Pullman
Journal:  Nucleic Acids Res       Date:  1986-11-25       Impact factor: 16.971

4.  A theoretical investigation on the sequence selective binding of mitoxantrone to double-stranded tetranucleotides.

Authors:  K X Chen; N Gresh; B Pullman
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

Review 5.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 6.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

7.  Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity.

Authors:  José Portugal
Journal:  BMC Pharmacol       Date:  2009-09-16

8.  Inhibitors of human immunodeficiency virus integrase.

Authors:  M R Fesen; K W Kohn; F Leteurtre; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

Review 10.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.